



*For immediate distribution*

## **BIORTHEX ANNOUNCES COMPANY RESTRUCTURING**

P  
R  
E  
S  
S  
  
R  
E  
L  
E  
A  
S  
E

**Montreal, CANADA, June 25, 2002** – Biorthex Inc. announced today that its Board of Directors has approved a strategic change in the Company's direction that will allow it to refocus its activities in order to achieve targeted results and maximize value for all investors and shareholders. Biorthex will concentrate its efforts on two major projects: the start of clinical trials for the Actipore™ PLF device in the United States and the upcoming launch of the Actipore™ ACF device. In addition in order to increase product awareness throughout the rest of the world, selective efforts will be made to expand the existing distribution network.

The Actipore™ PLF device is indicated for lower back pain due to degenerative disk disease. The United States represents a 70% of this \$250 million market. Therefore it is imperative that Biorthex Inc. enters such a significant marketplace as soon as possible. To do so, Biorthex will concentrate on these clinical trials which upon FDA approval will allow it to compete for market share in this spinal implant market.

The Actipore™ ACF device, indicated for cervical back pain also due to degenerative disk disease, represents a \$60 million market which is expected to grow to \$200 million within 5 years. There is currently only one cervical implant available for sale in the United States.

As a result of this refocusing effort, the Company's operations and activities will be streamlined, resulting in cost reduction measures that will result in a staff reduction of approximately 50% of its workforce.

Benoit Sicotte, newly appointed President and CEO of Biorthex commented: "Biorthex's management anticipates that this initiative will allow the company to get through this challenging economic period while still creating shareholder value. We have a great technology platform and intend to exploit it to its fullest" concluded Mr. Sicotte.

Biorthex Inc. is a biotechnology company that designs, develops and markets innovative products for the surgical treatment of spinal disorders to become a leader in the field of orthopaedics.

- 30 -

### **Information:**

Benoit Sicotte, Eng., M.B.A.  
President and CEO  
Biorthex Inc.  
(514) 382-4800, ext. 202

Michèle Jémus, CA, M.Sc.  
Vice President, Finance  
Biorthex Inc.  
(514) 382-4800, ext. 225

---

**Biorthex Inc.**

9001 l'Acadie Blvd., Suite 802, Montreal, Quebec H4N 3H5 CANADA

---

**Biorhex Inc.**

9001 l'Acadie Blvd., Suite 802, Montreal, Quebec H4N 3H5 CANADA